home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

46.76 -0.32 (-0.68%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

41 42 Next >

Will This Potential Approval Be a Winner for Sanofi's Shareholders? ↗

December 09, 2022

Sanofi and Regeneron's Dupixent moved closer to regulatory approval to treat another skin disease in the European Union.

Via The Motley Fool

Can Pfizer, Johnson & Johnson Continue Outperforming the Index?

December 09, 2022

Large-cap pharmaceuticals Pfizer and Johnson & Johnson are outperforming the broader market in the past year, particularly in the past three months.

Via MarketBeat

France Health Body Advises Unfavorable Opinion Regarding Valneva's COVID-19 Vaccine ↗

December 08, 2022

Via Benzinga

This Monster Dividend Stock Isn't Done Growing ↗

December 08, 2022

Is another deal on the way for Johnson & Johnson?

Via The Motley Fool

Revolution Medicines Regains Global Rights To Mid-Stage Cancer Program As Sanofi Terminates Collaboration ↗

December 08, 2022

Via Benzinga

Europe Approves Sanofi's Enjaymo For Rare Form Of Anemia ↗

November 17, 2022

Via Benzinga

Fusion Fuel (HTOO) Stock Is Up 11% on HUGE Deal News ↗

December 07, 2022

Fusion Fuel (HTOO) stock is heading higher on Wednesday after the company secured a deal with the Portuguese government.

Via InvestorPlace

Why Is TransCode Therapeutics (RNAZ) Stock Up 148% Today? ↗

December 07, 2022

TransCode Therapeutics (RNAZ) stock is rallying higher on Wednesday after the company withdrew plans for a secondary offering.

Via InvestorPlace

SNY Stock Alert: Why 1 Analyst Says Zantac Ruling Is ‘Best-Case Scenario’ for Drugmakers ↗

December 07, 2022

Sanofi (SNY) stock is in the news as one analyst believes the latest court ruling is the "best-case scenario" for the drugmaker.

Via InvestorPlace

Meta Criticized For Providing Extra Protection To Certain Users, Twitter HQ Bedrooms Under Regulatory Scrutiny, Juul Settles Over 5,000 Lawsuits: Top Stories Wednesday, Dec. 07 ↗

December 07, 2022

Benzinga

Via Benzinga

Relief To Pfizer, Sanofi As US Dismisses Several Lawsuits Associated With Zantac ↗

December 07, 2022

Via Benzinga

These 3 Stocks Escaped Tuesday's Market Downdraft ↗

December 06, 2022

Even a dour outlook for the broader stock market couldn't outweigh good news for these companies.

Via The Motley Fool

Why GSK Plc And Sanofi SA Stock Are Shooting Higher ↗

December 06, 2022

Shares of GSK plc (NYSE: GSK) and Sanofi SA (NASDAQ: SNY) are trading higher going into the close of Tuesday's session after the companies reportedly won a Zantac product liability lawsuit.

Via Benzinga

Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing

December 06, 2022

From Singapore Economic Development Board (EDB)A*STAR

Via ACN Newswire

Horizon Topples After J&J Pulls Out Of Bidding War, Leaving Amgen, Sanofi ↗

December 05, 2022

There are now two companies in the ring for a Horizon takeover.

Via Investor's Business Daily

Stock Market Rally Fights At Key Level On Powell, Inflation Data, Jobs Report: Weekly Review ↗

December 02, 2022

The S&P 500 is fighting for its 200-day, a critical level for the uptrend.

Via Investor's Business Daily

If Sanofi Opted For Takeover Of Horizon Therapeutics, It Would Be In Cash ↗

December 02, 2022

Via Benzinga

Why Horizon Therapeutics Stock Is Skyrocketing Today ↗

November 30, 2022

Three big drugmakers could be interested in acquiring Horizon.

Via The Motley Fool

Why Is Horizon Therapeutics (HZNP) Stock Up 30% Today? ↗

November 30, 2022

Horizon Therapeutics (HZNP) stock is rising higher on Wednesday following reports that the company is considering a buyout.

Via InvestorPlace

Are Tech Layoffs Going to Be a Headache for Alexandria Real Estate Equities? ↗

November 30, 2022

Tech layoffs are in the news, but life sciences companies seem to be doing better.

Via The Motley Fool

UK Drug Regulator Warns Of Severe Eye Reactions Associated With Sanofi/Regeneron's Dupixent ↗

November 30, 2022

Via Benzinga

iPhone Pro Shipments May Miss Consensus, Tesla Rival Charts Ambitious Expansion Plan In Mexico, Amazon Cloud Unit To Add More Employees: Top Stories Wednesday, Nov. 30 ↗

November 30, 2022

Reuters

Via Benzinga

Horizon Therapeutics Shares Jump On Confirmation Of Takeover Talks With Several Large Companies ↗

November 30, 2022

Via Benzinga

Horizon Therapeutics Rockets As It Considers Potential Bids From Amgen, J&J, Sanofi ↗

November 29, 2022

The three companies have until Jan. 10 to decide whether they want to buy Horizon.

Via Investor's Business Daily

First Drug That Can Delay Onset of Type 1 Diabetes Gets FDA Approval After Multiple Regulatory Hurdles ↗

November 18, 2022

Via Benzinga

Daily Stock Analysis: Sanofi - November 2022 Snapshot ↗

November 16, 2022

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. The company's decided in late 2019 to pull back from the cardio-metabolic...

Via Talk Markets

A Paradigm Shift In Healthcare Produces A Big Market Opportunity ↗

November 15, 2022

In a couple of years, Dario Heath could easily be a $100M+ company running 60%+ gross margins, be profitable and cash generating.

Via Talk Markets

Eli Lilly's Twitter Fiasco Continues As Drugmaker Reportedly Pulls 'Millions' In Twitter Ads ↗

November 14, 2022

The fallout from a fake account continued Monday as Lilly reportedly pulled Twitter ads.

Via Investor's Business Daily

Can This Company's Research Help Transform Regenerative Medicine As Its Lead Product Receives FDA IND Approval? ↗

November 14, 2022

Learn More about Organicell Regenerative Medicine, Inc. by gaining access to the latest research report In the medical community, the popularity of regenerative medicine is reportedly soaring primarily...

Via Benzinga

Week In Review: Insilico Signs Six-Drug Discovery Deal With Sanofi Worth Up To $1.2 Billion ↗

November 12, 2022

Insilico Medicine signed a six-drug research collaboration with Sanofi that could be worth up to $1.2 billion. Insilico will receive up to $21.5 million in upfront and target nomination fees for each...

Via Talk Markets

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

41 42 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com